Category: Edwards LifesciencesSyndicate content

Study: Heart valve coatings prolong durability

May 27, 2015 by Brad Perriello

A study of replacement heart valves treated with calcification-reducing coatings shows that the coatings prolong valve durability.

Study: Heart valve coatings prolong durability

Blood clots prompt trial pause for Edwards' Fortis mitral valve

May 19, 2015 by Brad Perriello

Edwards Lifesciences halts enrollment in a clinical trial of its Fortis mitral valve implant after some patients developed blood clots in the devices.

Blood clots force trial pause for Edwards' Fortis mitral valve

TAVI: Edwards CEO says Sapien 3 could hit U.S. market this year

April 24, 2015 by Brad Perriello

Edwards Lifesciences CEO Michael Mussallem says the company now expects the FDA to approve its next-generation Sapien 3 replacement heart valve this year.

TAVI: Edwards CEO says Sapien 3 could hit U.S. market this year

ACC 2015 Roundup: CTA no benefit, Abbott's MitraClip, Philips' IntelliSpace

March 16, 2015 by Brad Perriello

Screening coronary artery disease patients using computed-tomography angiography is no better than functional testing in improving outcomes, according to a large clinical study by the National Heart, Lung & Blood Institute, plus more from the annual meeting of the American College of Cardiology.

ACC 2015 Roundup: CTA no benefit, Abbott's MitraClip, Philips' IntelliSpace

A large clinical trial comparing computed-tomography angiography with functional testing found no benefit to clinical outcomes with CTA, which also exposes patients to large doses of radiation.

ACC 2015: Danish study finds TAVI safe for low-risk patients

March 16, 2015 by MassDevice

A Danish study presented at the American College of Cardiology's annual conference shows that transcatheter aortic valve implants are safe in low-risk patients.

ACC 2015: Danish study finds TAVI safe for low-risk patients

(Reuters) — Transcatheter aortic valve implantation is safe for low-risk patients, according to a study presented at the American College of Cardiology meeting in San Diego.

TAVI: Strong results for heart valves from Edwards Lifesciences, Medtronic

March 16, 2015 by Brad Perriello

Replacement heart valves made by Edwards Lifesciences and Medtronic once again dominate the American College of Cardiology's annual meeting, with long-term results for Edwards' Sapien and Medtronic's CoreValve complemented by even better data from their next-generation transcatheter aortic valve implants.

TAVI: Strong results for heart valves from Edwards Lifesciences, Medtronic

Transcatheter aortic valve implants once again took the spotlight at the annual meeting of the American College of Cardiology, with a spate of studies both confirming the long-term benefits of the replacement heart valves and showing that newer TAVI versions are even better.

Medtech's $33m lobbying spend last year hits 16-year high

March 9, 2015 by Brad Perriello

The lobbying spend in Washington hit a 16-year high of nearly $33 million in 2014, as the industry continued its fight to repeal Obamacare's medical device tax.

Medtech's $33m lobbying spend is an all-time high

The medical device industry's lobbying spend hit its highest point since 1998 last year, nearing $33 million, as the industry stepped up its campaign to repeal the medical device tax enacted as part of Obamacare.